Lexaria Bioscience Expands Pharmaceutical Division to Include Lipophilic Antiviral Active Molecules for COVID-19 Treatment
March 23rd, 2020
KELOWNA, BRITISH COLUMBIA / ACCESSWIRE / March 23, 2020 / Lexaria Bioscience Corp. (OTCQX:LXRP)(CSE:LXX) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, has expanded the scope and activities of its 100%-owned subsidiary Lexaria Pharmaceutical Corp., to investigate how Lexaria’s patented DehydraTECHTM drug delivery technology could enhance delivery and effectiveness of certain antiviral drugs in the fight against coronavirus disease COVID-19. Lexaria intends to expand collaboration with leading laboratories in North America and internationally as soon as possible.
Lexaria Pharmaceutical Business Unit
Within the Lexaria Pharmaceutical Corp. business unit resides Intellectual Property for enhanced delivery of drugs such as non-steroidal anti-inflammatories (“NSAIDs”), vitamins, hormone treatments utilizing estrogen or testosterone and phosphodiesterase (“PDE5”) inhibitors; with expansion now underway to include antiviral drugs as well. Lexaria’s patented DehydraTECH drug delivery technology enhances the way Active Pharmaceutical Ingredients (“APIs”) enter the bloodstream, promoting lower overall dosing and higher effectiveness for lipophilic active molecules, including the lipophilic antiviral drugs under investigation. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 16 patents granted and over 60 patents pending worldwide.
Lipophilic Antiviral Drug Delivery – Rationale
Researchers around the world are currently investigating various antiviral drugs as potential candidates to treat persons infected with coronavirus. Many of these drugs are fat soluble and known to present significant bioavailability challenges in successfully reaching the human bloodstream when administered in oral form. Lexaria has established itself as a scientific leader in oral delivery of fat soluble drugs.
DehydraTECH has been proven to reduce time of onset and increase bioavailability in every fat soluble drug with which it has been tested to date. When quantified, the increase in bioavailability can significantly reduce the drug dose required to treat a condition, thereby reducing treatment costs. In the case of COVID-19 where many millions of drug doses may be required worldwide, this has the potential to save billions of dollars and improve accessibility to positively effect healthcare on a global scale. Furthermore, DehydraTECH’s bioavailability enhancing effects are believed to be enabled in part by influencing a decrease in first pass liver metabolism for orally administered drugs. This, in turn, is thought to enable improved safety and tolerability for patients by maximizing the quantity of the ingested drug that traverses the GI tract and reaches the bloodstream without being degraded by or placing stress upon organs that process waste elimination.
Lexaria Pharmaceutical Corp. intends to investigate its leading-edge drug delivery technology throughout 2020 and 2021 to improve drug delivery efficiency for potential application for a number of virus-related diseases such as AIDS, Influenza and COVID-19.
Data-Driven R&D Program
Lexaria has completed the design phase and intends to conduct a pilot human pharmacokinetic (“PK”) exploratory study in healthy volunteers with three or more antiviral drugs that have previously been studied against other coronavirus strains, comparing DehydraTECH formulations to controls. Lexaria intends to conduct this first study at a leading Canadian university where a study design and plan has already been submitted for ethics board approval. Lexaria will provide further details upon successful conclusion of the review process, as well as study outcomes when available.
If the PK data are successful in demonstrating antiviral drug delivery efficiencies, Lexaria will provide that data to researchers around the world to enable additional practical research in utilization of similar antiviral drugs in combating COVID-19. Additional publicly reported data may include expanded PK and pharmacodynamic screening in appropriate disease models in animals to predict human effectiveness.
Pending positive outcomes from its planned research activities, Lexaria will aggressively engage with prospective strategic partners to improve drug development where applicable, in alignment with its business model as a drug delivery technology licensor and provider.
Stock Option Cancellation
Separately, Lexaria also announces that on March 23, 2020 it has cancelled, with the approval of the optionees, an aggregate of 3,268,000 stock options (the “Options”) having exercise prices ranging from US$0.37 to US$1.53. The Options were issued pursuant to the Company’s registered stock option plans and, as a result of such option cancellations, the Company will be terminating its 2007 Stock Option Plan as there are no longer any options issued pursuant to that plan, though other options remain granted from Lexaria’s other option plans.
Lexaria Bioscience Corp. is a global innovator in drug delivery platforms. Its patented DehydraTECH™ drug delivery technology changes the way API’s enter the bloodstream, promoting healthier ingestion methods, lower overall dosing and higher effectiveness for lipophilic active molecules. DehydraTECH increases bio-absorption; reduces time of onset; and can reduce drug costs for orally administered bioactive molecules including nicotine, vitamins, non-steroidal anti-inflammatory drugs (NSAIDs) and other molecules. Lexaria has licensed DehydraTECH to multiple companies for use in various oral application formats, including to a world-leading tobacco producer for the development of smokeless, oral-based nicotine products. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 16 patents granted and over 60 patents pending worldwide.
FOR FURTHER INFORMATION PLEASE CONTACT:
Lexaria Bioscience Corp.
Chris Bunka, CEO
This release includes forward-looking statements. Statements which are not historical facts are forward-looking statements. The Company makes forward-looking public statements concerning its expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, including statements that include words such as “anticipate,” “if,” “believe,” “plan,” “estimate,” “expect,” “intend,” “may,” “could,” “should,” “will,” and other similar expressions are forward-looking statements, including but not limited to: that any additional patent protection will be realized or that patent achievements will deliver material results. Such forward-looking statements are estimates reflecting the Company’s best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that other factors will not affect the accuracy of such forward-looking statements. Factors which could cause actual results to differ materially from those estimated by the Company include, but are not limited to, government regulation and regulatory approvals, managing and maintaining growth, the effect of adverse publicity, litigation, competition, scientific discovery, the patent application and approval process and other factors which may be identified from time to time in the Company’s public announcements and filings. There is no assurance that existing capital is sufficient for the Company’s needs or that it will be able to raise additional capital. There is no assurance the Company will be capable of developing, marketing, licensing, or selling products containing cannabinoids, nicotine, anti-viral or any other active ingredient. There is no assurance that any planned corporate activity, scientific research or study, business venture, letter of intent, technology licensing pursuit, patent application or allowance, consumer study, or any initiative will be pursued, or if pursued, will be successful. There is no assurance that any of Lexaria’s postulated uses, benefits, or advantages for the patented and patent-pending technology will in fact be realized in any manner or in any part. No statement herein has been evaluated by the Food and Drug Administration (FDA). Lexaria-produced products are not intended to diagnose, treat, cure or prevent any disease.
The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.
SOURCE: Lexaria Bioscience Corp.
This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.
Follow Us on Social Media
About CFN Media Group
CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.
Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.